Haemonetics (HAE) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Haemonetics Reports 2nd Quarter Fiscal 2016 Revenue of $220 Million and Adjusted EPS of $0.44, Affirms Recent Full Fiscal Year Guidance
November 4, 2015 6:00 AM ESTBRAINTREE, Mass., Nov. 4, 2015 /PRNewswire/ --
Product Growth Highlights
8% constant currency revenue increases in growth drivers in the second quarter, including:
11% growth in North America plasma disposables revenue 25% growth in TEG® diagnostics disposables revenue 6% growth in Emerging Markets disposables revenue, ex-RussiaHaemonetics Corporation (NYSE: HAE) reported second quarter fiscal 2016 revenue of $219.7 million, down 3%. Revenue was flat with the second quarter of fiscal 2015 in constant currency.Â
The Company reported GAAP net income of $12.9 million and GAAP net earnings per share of $0.25 in the second quarter of... More
